August 24, 2020
This article was originally published by Cancer Network The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy, according to the Janssen Pharmaceutical Companies of Johnson & Johnson, the...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand